Clinical Trial Update: UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib [Phase 2]

View source ↗

Summary

A Phase II open-label study evaluating the overall response rate of trametinib in multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Trametinib (trametinib)

Snippet

Sponsor: University of Arkansas | Conditions: Multiple Myeloma | Phase 2 | Status: WITHDRAWN